Ask AI
ProCE Banner Activity

Advances in Oral Targeted Therapies for HR+/HER2- Breast Cancer: Best Practices for Oncology Pharmacists

Slideset

Download these slides to enhance your ability to integrate oral targeted therapies for HR-positive/HER2-negative breast cancer into clinical practice to individualize patient care and improve outcomes.

Released: May 20, 2026

Share

Provided by

Provided by ProCE, LLC.

ProCE Banner

Supporters

Supported by an educational grant from AstraZeneca.

AstraZeneca

Target Audience

This activity has been designed to meet the educational needs of oncology pharmacists and other healthcare professionals caring for patients with breast cancer.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Apply the latest safety and efficacy evidence for oral targeted therapies to clinical practice to individualize the management of patients with HR-positive/HER2-negative breast cancer

  • Collaborate with patients, caregivers, and the multidisciplinary team to use evidence-based approaches for monitoring and managing adverse events associated with oral targeted therapies for HR-positive/HER2-negative breast cancer

  • Support adherence/persistence to oral targeted therapies in patients with HR-positive/HER2-negative breast cancer through expert-recommended communication strategies, tools, and resources